NASDAQ:KRYS Krystal Biotech (KRYS) Stock Forecast, Price & News $124.20 +7.36 (+6.30%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$116.51▼$124.2350-Day Range$77.89▼$120.4852-Week Range$49.17▼$124.23Volume389,174 shsAverage Volume241,300 shsMarket Capitalization$3.20 billionP/E RatioN/ADividend YieldN/APrice Target$134.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Krystal Biotech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside7.9% Upside$134.00 Price TargetShort InterestBearish5.47% of Float Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.55Based on 7 Articles This WeekInsider TradingSelling Shares$17.54 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.78) to ($1.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector668th out of 983 stocksBiological Products, Except Diagnostic Industry107th out of 164 stocks 1.5 Analyst's Opinion Consensus RatingKrystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $134.00, Krystal Biotech has a forecasted upside of 7.9% from its current price of $124.20.Amount of Analyst CoverageKrystal Biotech has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.47% of the float of Krystal Biotech has been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Krystal Biotech has recently decreased by 0.86%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKrystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Krystal Biotech is -0.87. Previous Next 3.1 News and Social Media Coverage News SentimentKrystal Biotech has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Krystal Biotech this week, compared to 4 articles on an average week.Search Interest3 people have searched for KRYS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows7 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,539,513.00 in company stock.Percentage Held by Insiders17.00% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.80% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Krystal Biotech are expected to grow in the coming year, from ($4.78) to ($1.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is -23.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is -23.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 6.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Krystal Biotech (NASDAQ:KRYS) StockKrystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company's wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. Krystal was founded by Krish Krishnan & Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.Read More Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address KRYS Stock News HeadlinesMay 30, 2023 | marketbeat.comKrystal Clear: Krystal Biotech Clears Resistance in Good VolumeRegulatory momentum, bullish Wall Street analysts and favorable technicals all suggest Krystal Biotech, Inc. may be a gem.June 2, 2023 | benzinga.comThinking about buying stock in Krystal Biotech, Axsome Therapeutics, 89bio, Scpharmaceuticals, or Decibel Therapeutics?June 2, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 29, 2023 | finance.yahoo.comAre Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 41%?May 27, 2023 | americanbankingnews.comChardan Capital Weighs in on Krystal Biotech, Inc.'s FY2023 Earnings (NASDAQ:KRYS)May 26, 2023 | americanbankingnews.comKrystal Biotech (NASDAQ:KRYS) Price Target Increased to $145.00 by Analysts at Stifel NicolausMay 25, 2023 | msn.comStifel Maintains Krystal Biotech (KRYS) Buy RecommendationMay 25, 2023 | americanbankingnews.comKathryn Romano Sells 25,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) StockJune 2, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 25, 2023 | americanbankingnews.comDaniel Janney Sells 50,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) StockMay 25, 2023 | americanbankingnews.comKathryn Romano Sells 28,428 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) StockMay 25, 2023 | americanbankingnews.comKrystal Biotech (NASDAQ:KRYS) Price Target Raised to $139.00May 25, 2023 | americanbankingnews.comFY2027 EPS Estimates for Krystal Biotech, Inc. Boosted by William Blair (NASDAQ:KRYS)May 25, 2023 | americanbankingnews.comQ3 2023 EPS Estimates for Krystal Biotech, Inc. (NASDAQ:KRYS) Raised by AnalystMay 24, 2023 | finanznachrichten.deOption Care Health, Inc.: Option Care Health Selected by Krystal Biotech as Part of a Limited Distribution Specialty Pharmacy Network for VYJUVEKMay 24, 2023 | msn.comOption Care, Amedisys in pact to offer Krystal Biotech’s skin disorder therapyMay 24, 2023 | americanbankingnews.comKrystal Biotech, Inc. (NASDAQ:KRYS) Forecasted to Post Q3 2023 Earnings of ($1.25) Per ShareMay 24, 2023 | americanbankingnews.comHC Wainwright Increases Krystal Biotech (NASDAQ:KRYS) Price Target to $139.00May 24, 2023 | americanbankingnews.comKrystal Biotech (NASDAQ:KRYS) Price Target Raised to $118.00May 24, 2023 | americanbankingnews.comKrystal Biotech (NASDAQ:KRYS) Shares Gap Up After Analyst UpgradeMay 23, 2023 | finance.yahoo.comOption Care Health Selected by Krystal Biotech as Part of a Limited Distribution Specialty Pharmacy Network for VYJUVEK™May 23, 2023 | msn.comGoldman Sachs Maintains Krystal Biotech (KRYS) Buy RecommendationMay 23, 2023 | msn.comB of A Securities Maintains Krystal Biotech (KRYS) Buy RecommendationMay 22, 2023 | msn.comUnlocking a $750 Million Opportunity: Krystal Biotech's Vyjuvek and its Potent Impact on Dystrophic Epidermolysis Bullosa TreatmentMay 22, 2023 | msn.comKrystal Biotech announces $160M private placementMay 22, 2023 | markets.businessinsider.comCSafe Providing Sustainable Thermal Protection for Vyjuvek Gene Therapy from Krystal BiotechMay 22, 2023 | finance.yahoo.comWhy Shares of Krystal Biotech Are Rising MondaySee More Headlines KRYS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRYS Company Calendar Last Earnings2/27/2023Today6/02/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KRYS CUSIPN/A CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees119Year Founded2017Price Target and Rating Average Stock Price Forecast$134.00 High Stock Price Forecast$148.00 Low Stock Price Forecast$118.00 Forecasted Upside/Downside+14.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-25.63% Return on Assets-23.86% Debt Debt-to-Equity RatioN/A Current Ratio10.13 Quick Ratio10.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$18.98 per share Price / Book6.14Miscellaneous Outstanding Shares25,800,000Free Float21,414,000Market Cap$3.01 billion OptionableNot Optionable Beta0.83 Social Links Key ExecutivesKrish S. KrishnanChairman, President & Chief Executive OfficerSuma M. KrishnanDirector, President-Research & DevelopmentGeorge ChenManager-Information Technology & CSVTrevor ParryVice President-Research & Scientific AffairsDavid GlynnGeneral Counsel-Commercial & ComplianceKey CompetitorsImmunovantNASDAQ:IMVTRevolution MedicinesNASDAQ:RVMDVir BiotechnologyNASDAQ:VIRBeam TherapeuticsNASDAQ:BEAMImmunocoreNASDAQ:IMCRView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 577 shares on 5/26/2023Ownership: 0.017%Capital Impact Advisors LLCBought 307 shares on 5/23/2023Ownership: 0.022%Kathryn RomanoSold 25,000 sharesTotal: $2.73 M ($109.04/share)Daniel JanneySold 50,000 sharesTotal: $4.75 M ($95.02/share)Kathryn RomanoSold 28,428 sharesTotal: $2.70 M ($95.05/share)View All Insider TransactionsView All Institutional Transactions KRYS Stock - Frequently Asked Questions Should I buy or sell Krystal Biotech stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRYS shares. View KRYS analyst ratings or view top-rated stocks. What is Krystal Biotech's stock price forecast for 2023? 6 brokers have issued 12-month target prices for Krystal Biotech's shares. Their KRYS share price forecasts range from $118.00 to $148.00. On average, they expect the company's share price to reach $134.00 in the next year. This suggests a possible upside of 14.9% from the stock's current price. View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts. How have KRYS shares performed in 2023? Krystal Biotech's stock was trading at $79.22 at the beginning of the year. Since then, KRYS stock has increased by 47.2% and is now trading at $116.61. View the best growth stocks for 2023 here. When is Krystal Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our KRYS earnings forecast. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) released its quarterly earnings data on Monday, February, 27th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.01. What ETFs hold Krystal Biotech's stock? ETFs with the largest weight of Krystal Biotech (NASDAQ:KRYS) stock in their portfolio include Jacob Forward ETF (JFWD), Franklin Genomic Advancements ETF (HELX), Invesco DWA Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA). When did Krystal Biotech IPO? (KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO. What is Krystal Biotech's stock symbol? Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS." Who are Krystal Biotech's major shareholders? Krystal Biotech's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (8.53%), Avoro Capital Advisors LLC (6.78%), BlackRock Inc. (6.66%), State Street Corp (3.98%), Credit Suisse AG (2.46%) and Pictet Asset Management SA (2.45%). Insiders that own company stock include Daniel Janney, Dino A Rossi, Kathryn Romano, Krish S Krishnan and Suma Krishnan. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Krystal Biotech's stock price today? One share of KRYS stock can currently be purchased for approximately $116.61. How much money does Krystal Biotech make? Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $3.01 billion. The company earns $-139,980,000.00 in net income (profit) each year or ($5.28) on an earnings per share basis. How many employees does Krystal Biotech have? The company employs 119 workers across the globe. How can I contact Krystal Biotech? Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com. This page (NASDAQ:KRYS) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.